Amgen 2007 Annual Report Download - page 49

Download and view the complete annual report

Please find page 49 of the 2007 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

as Senior Vice President, Quality and Compliance and in June 2001 he also became the Corporate Compliance
Officer. Previously, Dr. Bonanni held various management positions at Baxter International, Inc. from 1974 to
1999, including positions as Corporate Vice President, Regulatory and Clinical Affairs and Corporate Vice
President, Quality System.
Mr. Robert A. Bradway, age 45, became Executive Vice President and Chief Financial Officer in April
2007. He joined the Company in 2006 as Vice President, Operations Strategy. Previously, Mr. Bradway had an
18 year career at Morgan Stanley in New York and London where he was a managing director in investment
banking. Mr. Bradway led Morgan Stanley’s healthcare practice in Europe for several years and also ran Morgan
Stanley’s European banking department.
Mr. Thomas J. Flanagan, age 58, became Senior Vice President and Chief Information Officer in October
2006. From June 2004 to October 2006, Mr. Flanagan served as Vice President, Information Systems. From De-
cember 1995 to May 2004, Mr. Flanagan served in a variety of executive positions including Chief Information
Officer and Vice President, Global Service Delivery at MCI.
Mr. Brian McNamee, age 51, became Senior Vice President, Human Resources in June 2001. From No-
vember 1999 to June 2001, Mr. McNamee served as Vice President of Human Resources at Dell Computer Corp.
From 1998 to 1999, Mr. McNamee served as Senior Vice President, Human Resources for the National Broad-
casting Corporation, a division of GE. From July 1988 to November 1999, Mr. McNamee held human resource
positions at GE.
Mr. George J. Morrow, age 55, became Executive Vice President of Worldwide Sales and Marketing in Jan-
uary 2001 and became Executive Vice President, Global Commercial Operations in April 2003. From January
1999 to December 2000, Mr. Morrow was President and Chief Executive Officer of Glaxo Wellcome Inc.
(“Glaxo”), a subsidiary of GlaxoSmithKline. From January 1997 to December 1998, Mr. Morrow was Managing
Director of Glaxo Wellcome U.K., also a subsidiary of GlaxoSmithKline. From May 1993 to December 1996,
Mr. Morrow was Group Vice President for Commercial Operations of Glaxo. Mr. Morrow currently serves on
the Board of Directors of Align Technology, Inc.
Dr. Roger M. Perlmutter, age 55, became Executive Vice President of Research and Development in Jan-
uary 2001. From July 1999 to December 2000, Dr. Perlmutter was Executive Vice President, Worldwide Basic
Research and Preclinical Development of Merck Research Laboratories. From February 1999 to July 1999,
Dr. Perlmutter served as Executive Vice President of Merck Research Laboratories, and from February 1997 to
January 1999, as Senior Vice President of Merck Research Laboratories. From May 1989 to January 1997,
Dr. Perlmutter was also Chairman of the Department of Immunology, University of Washington, and from Jan-
uary 1991 to January 1997, Professor in the Departments of Immunology, Biochemistry and Medicine,
University of Washington. From July 1984 to January 1997, Dr. Perlmutter served as Investigator at the Howard
Hughes Medical Institute at the University of Washington. Dr. Perlmutter currently serves on the Board of Direc-
tors of StemCells, Inc.
Mr. David J. Scott, age 55, became Senior Vice President, General Counsel and Secretary in March 2004.
From May 1999 to February 2004, Mr. Scott served as Senior Vice President and General Counsel of Medtronic,
Inc. and also as Secretary from January 2000. From December 1997 to April 1999, Mr. Scott served as General
Counsel of London-based United Distillers & Vintners. Mr. Scott also served in executive roles at Grand Metro-
politan plc and RJR Nabisco, Inc., and was an attorney in private practice.
Geographic Area Financial Information
For financial information concerning the geographic areas in which we operate, see Note 11, “Segment in-
formation — Geographic information” to the Consolidated Financial Statements.
Investor Information
Financial and other information about us is available on our website (http://www.amgen.com) (This website
address is not intended to function as a hyperlink, and the information contained in our website is not intended to
37